Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature ; volume:53 ; number:07 ; year:2021 ; pages:413-424
Hormone and metabolic research ; 53, Heft 07 (2021), 413-424
- Beteiligte Personen und Organisationen
-
Sari, Ramazan
Altinoz, Meric A.
Ozlu, Eylem Burcu Kahraman
Sav, Aydin
Danyeli, Ayca Ersen
Baskan, Ozdil
Er, Ozlem
Elmaci, Ilhan
- DOI
-
10.1055/a-1525-2131
- URN
-
urn:nbn:de:101:1-2021083013412860476872
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sari, Ramazan
- Altinoz, Meric A.
- Ozlu, Eylem Burcu Kahraman
- Sav, Aydin
- Danyeli, Ayca Ersen
- Baskan, Ozdil
- Er, Ozlem
- Elmaci, Ilhan
Ähnliche Objekte (12)
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
A bitopic agonist bound to the dopamine 3 receptor reveals a selectivity site
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas